지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 259 - 266 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice.
Methods: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety.
Results: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients.
Conclusions: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
목차
등록된 정보가 없습니다.
참고문헌 (33)
참고문헌 신청
World Health Organization / 2014 / WHO fact sheet 164-hepatitis C
Kim AI / 2005 / Treatment of hepatitis C / Am J Med 118:808~815
Ghany MG / 2009 / Diagnosis, management, and treatment of hepatitis C: an update / Hepatology 49:1335~1374
Gower E / 2014 / Global epidemiology and genotype distribution of the hepatitis C virus infection / J Hepatol 61(1 Suppl):S45~S57
European Association for the Study of the Liver / 2011 / EASL Clinical Practice Guidelines: Management of hepatitis C virus infection / J Hepatol 55:245~264
Kim AI / 2005 / Treatment of hepatitis C / Am J Med 118:808~815
Ghany MG / 2009 / Diagnosis, management, and treatment of hepatitis C: an update / Hepatology 49:1335~1374
Gower E / 2014 / Global epidemiology and genotype distribution of the hepatitis C virus infection / J Hepatol 61(1 Suppl):S45~S57
European Association for the Study of the Liver / 2011 / EASL Clinical Practice Guidelines: Management of hepatitis C virus infection / J Hepatol 55:245~264
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
Gut and Liver
2019 .01
-
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Clinical and Molecular Hepatology
2017 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
Gut and Liver
2020 .01
-
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
Journal of Korean Medical Science
2019 .01
-
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
Gut and Liver
2017 .01
-
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
Gut and Liver
2018 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Treatment Strategy on Hepatitis C Treatment In Liver Transplant Settings
Clinical Transplantation and Research
2016 .01
-
Hepatitis C Viral Infection in Children: Updated Review
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection
Gut and Liver
2015 .01
-
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
Journal of Korean Medical Science
2016 .01
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Clinical and Molecular Hepatology
2020 .01
-
Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea
Infection and Chemotherapy
2024 .09
-
Patients with Liver Cirrhosis
대한외과학회 학술대회 초록집
2021 .11
-
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
Gut and Liver
2022 .11
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
Clinical and Molecular Hepatology
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0